Epileptic Seizure Prediction System (ESPS) - Predicting and preventing epileptic seizures based on respiratory biofeedback & machine learning.
One of 10,000+ projects Taiyo tracks in Ireland.
Source: EU Funding & Tenders Portal
Epilepsy is one of the most common nervous system disorders and affects more than 50M people worldwide. The majority of new-onset cases occur in elderly and children. Currently there is no cure for epilepsy. Although antiepileptic drugs can help, one third of all patients do not respond to any pharmacological intervention. This staggering number has not changed in decades, despite over 14 new ther
- Status
- Closed
- Sector
- Hospital
- Location
- Ireland
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Epileptic Seizure Prediction System (ESPS) - Predicting and preventing epileptic seizures based on respiratory biofeedback & machine learning.
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Epilepsy is one of the most common nervous system disorders and affects more than 50M people worldwide. The majority of new-onset cases occur in elderly and children. Currently there is no cure for epilepsy. Although antiepileptic drugs can help, one third of all patients do not respond to any pharmacological intervention. This staggering number has not changed in decades, despite over 14 new therapies entering the market. The unpredictable nature of seizures causes the largest burden for patients as it literally disrupts their lives. Patients with several seizures a week are hesitant to leave the house & find it hard to obtain employment. Reliably predicting seizures enables an independent life for the patient and at the same time reduces healthcare costs caused by clinician visits, injuries & caretaking. iBreve’s new patent-pending wearable technology analyzes respiratory patterns in real-time, enabling market applications for seizure prediction, respiratory treatment & stress management. iBreve’s technology received interest from Harvard’s Boston Children’s Hospital to be included in clinical trials for seizure detection & prediction. The ESPS machine learning algorithm calculates seizure probability & intensity and if desired an alert is sent to the patient’s caregiver. The tracking and analysis of seizures can be shared with clinicians & allows to personalize treatment. Main objective of this feasibility study is the development of a comprehensive business plan to evaluate the opportunities & risks of introducing ESPS into the homecare market. All project activities follow the Healthcare Innovation Cycle methodology & are structured around 4 development pillars - Technology, Market & Business, Clinical and Regulatory. The introduction of ESPS is prone to disrupt the epilepsy market by reducing treatment costs per patient by up to 70%. Thus, saving 14B€ in health care costs in Europe alone and creating a major shift towards preventive & personalized treatment. |
Location
Country | Ireland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Ireland
- Glanbia Ingredients Ireland (GIL) Dairy Processing Facility, Belview
- Bristol Myers Squibb Biologics Manufacturing Facility, County Dublin
- SAFC Pharma API Manufacturing Expansion, Republic of Ireland
- Pfizer’s Biotechnology Campus, Clondalkin, Ireland
- Janssen Sciences’ Biomedicines Manufacturing Facility, Ringaskiddy, Ireland
- Centocor Biopharmaceutical
- Genzyme Manufacturing Expansion, Waterford
- Pfizer’s Synthesis Facility, Ringaskiddy, Ireland
